课题基金 / 基金详情

Novel Therapeutics for Long QT Syndrome

Novel Therapeutics for Long QT Syndrome
长 QT 综合征的新疗法
批准号:
10897465
负责人:
Masayuki Yazawa
金额:
$16.53万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-09-22 至 2024-08-31

项目摘要

项目成果

Masayuki Yazawa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary: Abnormal ion channel function in heart muscle cells induces cardiac arrhythmias such as long QT syndrome. In preliminary experiments using pharmaceutical approach, we found that activation of Sigma 1 receptor could alleviate the cellular phenotypes in human induced pluripotent stem cell (iPSC) and mouse models of the genetic cardiac arrhythmias. The goal of this study is to examine the molecular mechanism underlying the beneficial effect of Sigma receptor 1 activation on the phenotypes in cardiac ion channel regulation, action potentials, contraction, mitochondrial function and gene expression in the genetic arrhythmia models. We will use human iPSC and rodent models to accomplish our goal. In addition, we will design and develop new Sigma 1 receptor agonists that are more suitable for cardiac arrhythmias, taking advantage of our expertise in medicinal chemistry. Therefore, our translational study will provide new opportunity of drug development for the genetic syndromic disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutics for Timothy Syndrome and Related Cardiac Channelopathy
Novel Therapeutics for Long QT Syndrome
Molecular mechanisms underlying cardiac sodium channelopathy
Molecular mechanisms underlying cardiac sodium channelopathy
海外基金